Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure Inc (XCUR) is a pioneering biotechnology company developing nucleic acid therapies through its proprietary Spherical Nucleic Acid (SNA) platform. This page serves as the definitive source for verified news and press releases related to the company’s advancements in immunomodulatory treatments, gene silencing innovations, and therapeutic applications across oncology, inflammatory disorders, and neurological conditions.
Access real-time updates on Exicure’s clinical progress, regulatory milestones, and strategic partnerships. Our curated collection includes announcements on SNA technology breakthroughs, trial results, and research collaborations, providing stakeholders with a comprehensive view of the company’s scientific and operational trajectory.
Key content categories include clinical trial updates, regulatory filings, technology licensing agreements, and peer-reviewed research highlights. Each update is structured to help investors and researchers assess Exicure’s position in the competitive biotech landscape while maintaining strict adherence to factual reporting standards.
Bookmark this page for streamlined access to Exicure’s latest developments, and check back regularly for authoritative insights into one of biotechnology’s most innovative nucleic acid delivery platforms.
Exicure, Inc. (Nasdaq: XCUR) reported its Q2 2024 financial results, revealing a challenging financial position. The company's cash and cash equivalents decreased to $0.5 million as of June 30, 2024, from $0.8 million at the end of 2023. Exicure's net loss narrowed to $0.6 million in Q2 2024, compared to $5.8 million in Q2 2023, primarily due to reduced operations and cost-cutting measures. General and administrative expenses decreased significantly to $1.2 million, down from $5.6 million in the same quarter last year. The company generated $0.6 million in other income from selling clinical product samples. However, Exicure faces a critical cash shortage and urgently needs substantial additional financing to continue operations and explore strategic alternatives.
Exicure (Nasdaq: XCUR) has appointed Anna Chukaeva as Senior Vice President, Head of Corporate Development and Bioinformatics. Anna will lead investments, acquisitions, and strategic partnerships, while also focusing on leveraging data and AI for drug discovery and diagnostics.
Anna's background includes co-founding Carta Healthcare, an AI healthcare data company that raised over $50 million in venture financing. At Carta, she led a 40-person engineering and product team, developing enterprise-scale data software products adopted by hospital systems nationwide. Anna holds a bachelor's degree in mathematics, a master's in economics, and an MBA from Stanford.
Exicure (Nasdaq: XCUR) has received a positive listing determination from the Nasdaq Hearings Panel. The panel has decided to continue the company's listing on The Nasdaq Capital Market, subject to Exicure demonstrating compliance with all applicable criteria by September 16, 2024. This decision provides Exicure with additional time to meet the necessary requirements for maintaining its Nasdaq listing. The company is actively working to satisfy the terms of the panel's decision and ensure its continued presence on the Nasdaq exchange.
Exicure (Nasdaq: XCUR), an early-stage biotech firm, reported its Q1 2024 financial results. The company has halted all R&D activities, focusing on strategic alternatives. Cash and equivalents dropped to $0.4 million by March 31, 2024, from $0.8 million in December 2023, further dipping to $0.2 million by May 2024. A $0.7 million loan was secured in May 2024. Revenue included a $0.5 million initial payment from a patent license agreement for cavrotolimod. R&D expenses decreased to $0 versus $1.4 million YoY, and G&A expenses fell to $1.3 million from $3.1 million YoY. Net loss improved to $0.8 million from $4.4 million YoY. Management expresses urgent need for additional financing to sustain operations and explore strategic options.
Exicure (Nasdaq: XCUR) reported its full-year 2023 financial results, highlighting a significant reduction in operations and financial strain.
As of December 31, 2023, the company’s cash and cash equivalents stood at $0.8 million, down from $8.6 million in 2022, further dropping to $0.2 million by May 31, 2024. Exicure received a $0.7 million loan from DGP Co., to cover immediate financial needs.
Research and development expenses decreased drastically to $1.4 million from $19.8 million in 2022, following the suspension of clinical, preclinical, and discovery program activities.
General and administrative expenses rose to $12.7 million from $10.9 million. The net loss for the year increased to $16.9 million, significantly higher than the $2.6 million loss in 2022, due to the absence of revenue.
Management disclosed concerns over the company's ability to continue operations without substantial additional financing in the near term.
Exicure has received a delisting determination notice from Nasdaq for not filing its Form 10-K for 2023 and Form 10-Q for Q1 2024 by the extended deadline of May 20, 2024. Trading of Exicure's stock will be suspended on May 30, 2024, unless the company appeals by May 28, 2024. Failure to appeal will result in a Form 25-NSE being filed with the SEC, removing Exicure's securities from Nasdaq. Additionally, Exicure has not held its 2023 Annual Meeting of Stockholders, which is another basis for delisting. Exicure intends to appeal and file the required forms as soon as possible.
Exicure (Nasdaq: XCUR) reported its third-quarter 2023 financial results. The company, which halted all R&D activities in September 2022 to explore strategic alternatives, had cash and equivalents of $0.9 million as of September 30, 2023, down from $8.6 million at the end of 2022, and further decreased to $0.2 million by April 30, 2024.
R&D expenses were $0 for Q3 2023, compared to $4.8 million for the same period in 2022. General and administrative expenses remained steady at $2.4 million. The net loss was $5.3 million, slightly up from $5.2 million in Q3 2022, mainly due to a loss on debt securities.
The company urgently needs additional funding to continue operations, as current cash levels are insufficient.
FAQ
What is the current stock price of Exicure (XCUR)?
What is the market cap of Exicure (XCUR)?
